The study focuses on the assessment of
LY170680 as an inhibitor of leukotrienes C4, D4, and E4. In laboratory settings, LY170680 demonstrated strong, selective antagonism against LTD4 and LTE4, causing a concentration-dependent shift in response curves in guinea pig ileum and trachea, with pA2 values indicating its potency. It also acted as a moderate antagonist to LTC4-induced responses in guinea pig ileum but did not affect contractions caused by histamine, prostaglandins, or acetylcholine. Furthermore, LY170680 reduced the effects of LTC4 on trachea non-competitively.
When administered intravenously, LY170680 decreased the decline in lung compliance and the increase in total pulmonary resistance in anesthetized and ventilated guinea pigs, respectively, in a dose-dependent manner. It was also effective in reducing the response to antigen challenge in sensitized animals that had been pretreated with other medications. However, when taken orally, its effectiveness was moderate in preventing the increase in total pulmonary resistance induced by LTD4.
Inhalation of LY170680 was notably effective in preventing the increase in total pulmonary resistance caused by aerosolized LTD4, with a small amount delivered via nebulizer causing a significant shift in the dose-response curve. Additionally, inhaled LY170680 reduced the volume of trapped gas in the lungs after exposure to aerosolized leukotrienes, with a sustained effect for several hours. However, it did not impact gas trapping caused by histamine.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
